• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

经导管主动脉瓣置换术后瓦尔萨尔瓦窦血栓的最佳抗栓治疗方案是什么？

What Is the Optimal Antithrombotic Therapy for Valsalva Thrombus Following Transcatheter Aortic Valve Replacement?

作者信息

Kato Yuta, Kawahira Yuto, Miyazaki Midori, Hirata Tetsuo, Kuwahara Go, Sugihara Makoto, Miura Shinichiro

机构信息

Department of Cardiology, Fukuoka University Hospital, Fukuoka, Japan.

Department of Clinical Laboratory and Transfusion, Fukuoka University Hospital, Fukuoka, Japan.

出版信息

JACC Case Rep. 2024 Aug 21;29(16):102455. doi: 10.1016/j.jaccas.2024.102455.

DOI:10.1016/j.jaccas.2024.102455
PMID:39295789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11405946/
Abstract

Thrombus formation between the native sinus of Valsalva and the implanted transcatheter heart valve is a rare complication that may be associated with an increased risk for thrombotic complications. This paper presents the course of 3 cases with Valsalva thrombus, with a focus on the management of antithrombotic therapy.

摘要

在主动脉瓣窦与植入的经导管心脏瓣膜之间形成血栓是一种罕见的并发症，可能与血栓形成并发症风险增加相关。本文介绍了3例主动脉瓣窦血栓患者的病程，重点关注抗栓治疗的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/898e/11405946/6003ac2009f9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/898e/11405946/3785dd6e73ac/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/898e/11405946/6003ac2009f9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/898e/11405946/3785dd6e73ac/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/898e/11405946/6003ac2009f9/gr1.jpg

相似文献

1
What Is the Optimal Antithrombotic Therapy for Valsalva Thrombus Following Transcatheter Aortic Valve Replacement?经导管主动脉瓣置换术后瓦尔萨尔瓦窦血栓的最佳抗栓治疗方案是什么？
JACC Case Rep. 2024 Aug 21;29(16):102455. doi: 10.1016/j.jaccas.2024.102455.
2
Silent Valsalva thrombus between the native Valsalva and balloon-expandable transcatheter heart valve: multicentre Japanese registry analysis.自体瓦氏窦与球囊扩张式经导管心脏瓣膜之间的沉默性瓦氏窦血栓：多中心日本注册研究分析。
EuroIntervention. 2019 Nov 20;15(10):892-899. doi: 10.4244/EIJ-D-19-00370.
3
Frequency, Predictors, and Clinical Impact of Valvular and Perivalvular Thrombus After Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后瓣叶及瓣周血栓的发生率、预测因素及临床影响。
JACC Cardiovasc Interv. 2023 Dec 25;16(24):2967-2981. doi: 10.1016/j.jcin.2023.10.024.
4
Optimal antithrombotic strategy following valve-in-valve transcatheter aortic and mitral valve replacement.经导管主动脉瓣和二尖瓣置换术后的最佳抗栓策略。
J Thorac Dis. 2024 Feb 29;16(2):1565-1575. doi: 10.21037/jtd-23-1313. Epub 2024 Jan 24.
5
Sinus of Valsalva Thrombosis Detected on Computed Tomography after Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后计算机断层扫描检测到的瓦尔萨尔瓦窦血栓形成
Korean Circ J. 2020 Jul;50(7):572-582. doi: 10.4070/kcj.2019.0385. Epub 2020 Mar 17.
6
Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.经导管主动脉瓣置换术患者中存在的心房颤动患者的抗栓治疗和临床结局的变化：来自胸外科医生学会/美国心脏病学会经导管瓣膜治疗登记处的见解。
Circ Cardiovasc Interv. 2021 Apr;14(4):e009963. doi: 10.1161/CIRCINTERVENTIONS.120.009963. Epub 2021 Apr 20.
7
Aortic Valve Replacement and Exclusion of Sinus of Valsalva Aneurysm With Balloon-Expandable Transcatheter Aortic Valve.经皮球囊扩张式主动脉瓣置换术联合主动脉窦瘤封堵术
JACC Case Rep. 2022 Jul 6;4(13):787-789. doi: 10.1016/j.jaccas.2022.05.013.
8
Antithrombotic therapy after transcatheter aortic valve implantation.经导管主动脉瓣植入术后的抗血栓治疗。
Expert Rev Med Devices. 2022 Jun;19(6):499-513. doi: 10.1080/17434440.2022.2106853. Epub 2022 Aug 7.
9
Coronary Access After Transcatheter Aortic Valve Replacement With Commissural Alignment: The ALIGN-ACCESS Study.经导管主动脉瓣置换术联合瓣叶对齐后的冠状动脉通路：ALIGN-ACCESS研究
Circ Cardiovasc Interv. 2022 Feb;15(2):e011045. doi: 10.1161/CIRCINTERVENTIONS.121.011045. Epub 2022 Feb 15.
10
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后的抗血栓治疗。
JACC Cardiovasc Interv. 2021 Aug 9;14(15):1688-1703. doi: 10.1016/j.jcin.2021.06.020.

本文引用的文献

1
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.经导管主动脉瓣置换术在五年内的低危患者中的应用。
N Engl J Med. 2023 Nov 23;389(21):1949-1960. doi: 10.1056/NEJMoa2307447. Epub 2023 Oct 24.
2
Long-Term Follow-Up of Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement.经导管主动脉瓣置换术后瓣叶低密度增厚的长期随访
JACC Cardiovasc Interv. 2022 Jun 13;15(11):1113-1122. doi: 10.1016/j.jcin.2022.04.018.
3
Aortic Sinus Contrast Retention During TAVR: A Warning Sign Preceding a Potential Thrombotic Complication.
经导管主动脉瓣置换术期间主动脉窦造影剂滞留：潜在血栓形成并发症的预警信号。
JACC Case Rep. 2022 Jun 1;4(11):666-670. doi: 10.1016/j.jaccas.2022.03.031.
4
Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement: A Meta-Analysis.经导管主动脉瓣置换术后亚临床瓣叶血栓形成：一项荟萃分析。
JACC Cardiovasc Interv. 2021 Dec 27;14(24):2643-2656. doi: 10.1016/j.jcin.2021.09.019.
5
Sinus of Valsalva Thrombosis Following Transcatheter Aortic Valve Replacement in a Bicuspid Aortic Valve.二叶式主动脉瓣经导管主动脉瓣置换术后的主动脉窦血栓形成
JACC Cardiovasc Interv. 2020 Aug 10;13(15):1828-1830. doi: 10.1016/j.jcin.2020.03.051. Epub 2020 Jun 10.
6
Computed Tomography Features of Cuspal Thrombosis and Subvalvular Tissue Ingrowth after Transcatheter Aortic Valve Implantation.经导管主动脉瓣植入术后瓣叶血栓和瓣下组织内生长的 CT 特征。
Am J Cardiol. 2020 Feb 15;125(4):597-606. doi: 10.1016/j.amjcard.2019.11.015. Epub 2019 Nov 21.
7
Silent Valsalva thrombus between the native Valsalva and balloon-expandable transcatheter heart valve: multicentre Japanese registry analysis.自体瓦氏窦与球囊扩张式经导管心脏瓣膜之间的沉默性瓦氏窦血栓：多中心日本注册研究分析。
EuroIntervention. 2019 Nov 20;15(10):892-899. doi: 10.4244/EIJ-D-19-00370.
8
Natural history of subclinical leaflet thrombosis affecting motion in bioprosthetic aortic valves.生物瓣主动脉瓣活动受影响的亚临床瓣叶血栓形成的自然史。
Eur Heart J. 2017 Jul 21;38(28):2201-2207. doi: 10.1093/eurheartj/ehx369.